Removal or ablation of asymptomatic lung metastases should be reconsidered

Macbeth, Fergus, Fallowfield, Lesley, Treasure, Elizabeth, Ahmad, Irfan, Zheng, Yan and Treasure, Tom 2023. Removal or ablation of asymptomatic lung metastases should be reconsidered. BMJ 383 , e073042. 10.1136/bmj-2022-073042

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

The lungs are the commonest site of systemic cancer metastases. Surgical resection has been used for over 50 years,1 and since 1995, when the term oligometastases was proposed (box 1), it is increasingly justified by framing it as an “opportunity” for curative local treatment in patients with “oligometastasis.”23 Less invasive treatments—ablation by stereotactic ablative radiotherapy (SABR) or image guided thermal ablation—with the same objective are also being more widely used in Europe and North America. NHS England commissioned ablative radiotherapy for metastases in 2021,4 and in 2023 three international professional societies published clinical practice guidelines on the removal or ablation of lung metastases.56

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Centre for Trials Research (CNTRR)
Publisher:	BMJ Publishing Group
ISSN:	1756-1833
Date of First Compliant Deposit:	22 March 2024
Date of Acceptance:	5 October 2023
Last Modified:	05 Apr 2024 14:00
URI:	https://orca.cardiff.ac.uk/id/eprint/167511

Actions (repository staff only)

Edit Item